HCmed Innovations Co., Ltd. (6934) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for HCmed Innovations Co., Ltd. (6934:TWSE), powered by AI.

Current Price
$83.10
P/E Ratio
-32.1
Market Cap
2.5B
Sector
Healthcare
What is the HCmed Innovations Co., Ltd. stock price forecast?

HCmed Innovations Co., Ltd. is currently trading at $83.10. View real-time AI analysis on Alpha Lenz.

What is HCmed Innovations Co., Ltd. insider trading activity?

View the latest insider trading data for HCmed Innovations Co., Ltd. on Alpha Lenz.

What is HCmed Innovations Co., Ltd.'s P/E ratio?

HCmed Innovations Co., Ltd.'s P/E ratio is -32.1.

HCmed Innovations Co., Ltd.

TWSE · 6934
NT$83.10-2.00(-2.35%)
Ask about HCmed Innovations Co., Ltd.'s future dividend policy...
Alpha Chat Insight

HCmed Innovations Co., Ltd. trades at a P/E of -32.1 (undervalued) with modest ROE of -32.2%. 3Y revenue CAGR of 37.9% highlights clear growth momentum.

Ask for details

Company Overview

HCmed Innovations Co., Ltd. is a health technology company that specializes in the development, manufacturing, and sales of advanced handheld medical nebulizers. Its primary focus lies in providing vibrating mesh nebulizers, which are engineered to effectively deliver liquid medications to the lower respiratory tract. This technology serves patients with conditions such as chronic obstructive pulmonary disease, asthma, cystic fibrosis, and respiratory infections. HCmed Innovations extends its capabilities to pharmaceutical partners through contract development and manufacturing organization (CDMO) services for drug-specific nebulizer systems, supporting the design and optimization of inhalation therapies. By ensuring compatibility with various drug formulations and adhering to rigorous pharmacopoeia guidelines, the company plays a key role in the medical equipment and biotechnology sectors. HCmed Innovations has established a global footprint, distributing its products across the United States, Taiwan, Switzerland, Israel, and the United Kingdom, and bolsters its market significance by contributing to the advancement of respiratory care and precision drug delivery technology.

CEOMr. Jason Cheng
SectorHealthcare
IndustryMedical Devices
0

Company Statistics

FY 2024

Profile

NT$2.51BMarket Cap
NT$141.61MRevenue
0.00Shares Out
0Employees

Margins

70.37%Gross
-18.79%EBITDA
-26.55%Operating
-35.96%Pre-Tax
-55.23%Net

Valuation

-32.09P/E
11.99P/B
17.72EV/Sales
-92.20EV/EBITDA
-57.13P/FCF

Growth (CAGR)

37.85%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-27.31%ROA
-32.16%ROE
-17.70%ROIC

Financial Health

NT$65.83MCash & Cash Equivalents
NT$-28.35MNet Debt
17.90%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

HCmed Innovations Co., Ltd. (ticker: 6934) is a company listed on TWSE in the Healthcare sector (Medical Devices). Market cap is $2.5B.

The current price is 83.1 with a P/E ratio of -32.09x and P/B of 11.99x.

ROE is -32.16% and operating margin is -26.55%. Annual revenue is $142M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
HCmed Innovations Co., Ltd. (6934) Stock Forecast 2026 $83.10 — Price, Financials & Analyst Targets | Alpha Lenz